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Introduction
Carcinoma of the prostate, more commonly known as prostate 
cancer, is a malignant tumor that develops on the prostate –a 
male organ that wraps around the urethra. Prostate cancer can 
occur in many different forms, such as carcinoid, small-cell tu-
mors, and ductal carcinoma, however, these types are extremely 
rare and little is known about which treatment most effectively 
eliminates them. The vast majority of cases are adenocarcinoma, 
a tumor that originates in the gland cells. Prostatic adenocarcino-
ma is observed in over 95 percent of patients (National Cancer 
Institute 2014) and affects 15 percent of men predominantly 
above the age of 66, making it the most common cancer among 
American males (SEER 2014). Fortunately, prostate cancer tends 
to grow extremely slowly, and early treatment can often yield 
high survival rates. The most common treatment interventions 
for prostate cancer include surgery or radiation therapy. Within 
radiation therapy there are two methods, external beam radia-
tion therapy (EBRT) and internal radiation therapy. The latter, also 
referred to as brachytherapy, involves the placement of radioac-
tive pellets within the prostate gland that release a highly con-
centrated dose of radiation to eliminate the cancerous growth. 
External beam radiation therapy is employed by using a linear 
accelerator to accelerate electrons close to the speed of light 
and strike them against a metal plate. On impact, high-energy, 
ionizing photons are produced, which travel towards the targeted 
cancerous cells. The high amount of energy in the photons can 
irreparably damage vital structures in the cell such as DNA, RNA, 
or protein. Photons are able to directly harm the cancerous cells’ 
DNA by energizing its electrons and pulling them out of their 
orbits. This produces free radicals, causing irreversible damage by 
altering the chemical structure of the nucleotides. Ionizing radi-
ation can also delete, fragment, and translocate the nucleotides. 
Radiation can also indirectly harm DNA when photons collide 
with a cell’s water molecules and energize its electrons. When 
a water molecule’s excited electrons bounce out of their orbits 
it produces a hydroxyl ion (OH-). The hydroxyl ion is then able 
to extract a hydrogen atom from the deoxyribose part of the 
DNA, ruining the nucleotide’s chemical configuration. Direct or 
indirect radiation damage to a cancerous cell’s DNA is usually 
lethal. This is because the uncontrollable growth of the prostate 
cancer involves the mutation of the tumor suppressor gene TP53 
(Wang et al. 1997). The protein that TP53 codes for is not only 
responsible for regulating the cell cycle, it is also responsible 
initiating DNA repair. As a result, cancerous cells are ineffective 
at repairing radiated DNA, and the cell’s ability to proliferate is 
practically destroyed. Damaging 1000 nucleotides in DNA only 
takes one cobalt grey equivalent –the unit measure of radiation 
used during treatment. 
Although external beam is an effective form of treatment, it also 
delivers radiation to surrounding healthy tissue. This is because 
before the advent of image guided treatment, physicians had to 
target the entire prostate to ensure that the entire tumor was 
radiated. Additionally, since the dose of radiation is gradually re-
duced as the beam passes through the patient, tissue directly in 
front of the tumor must be radiated to the prescribed dose. This 
leaves a track of radiation damage as the photons enter the body 
until it reaches the tumor. Furthermore, photons are massless 
particles and are not stopped or slowed down when they impact 
body tissue. This causes healthy tissue behind the tumor to re-
ceive radiation when photons travel past the tumor. Radiation to 
nearby healthy tissue often causes gastrointestinal and genitouri-
nary toxicity, which can impair the patient’s quality of life. 
Advances in radiotherapy have greatly reduced these problems. 
The advent of three-dimensional conformal radiotherapy (3D-
CRT) helps radiation oncologists treat prostate cancer more ef-
fectively. This sophisticated computer program creates a three-di-
mensional map to conform the radiation beam to the shape of 
the cancer and its surrounding normal tissues. Concentrating the 
beam more accurately to the cancerous area reduces the expo-
sure of normal tissue to radiation, further reducing side effects 
after treatment. More recent advances in high precision target-
ing have led to intensity-modulated radiotherapy (IMRT), where 
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there is an even more effective manipulation of the radiation 
beam. The beam in IMRT is divided into multiple ‘beamlets’, aimed 
at the target from different directions. The ‘beamlets’’ shape and 
intensity are adjusted to avoid radiating nearby healthy tissue. By 
taking advantage of intensity-modulated ‘beamlets’, IMRT is able 
to deliver higher doses of radiation to the prostate. This arguably 
ensures greater eradication of cancerous cells while sparing even 
more healthy tissue than 3D-CRT. Additional advances include 
image-guided radiotherapy, which provides more accuracy to the 
targeted area in the event that patients or the organs inside them 
move during treatment. 
Despite all the improvements in radiotherapy healthy tissue be-
hind the tumor is still getting bombarded with radiation. Proton 
therapy is able to stop this. Proton therapy involves the ther-
apeutic use of protons to radiate the DNA of cancerous cells. 
Protons are positively charged heavy particles, approximately 
1800 times the mass of an electron. Therefore, protons need a 
particle accelerator to strip hydrogen atoms of their electrons, 
accelerate them to nearly the speed of light, and shoot them into 
tumors. Particle accelerators, either cyclotrons or synchrotrons, 
require an enormous amount of space, which makes the cost 
of a particle accelerator exceed 100 million dollars (National 
Association for Proton Therapy 2010). Upon entering the body, 
protons slow down due to their heavy weight and their attrac-
tion to the electrons in the body’s cells. Consequently, physicians 
must program the particle accelerators to provide the protons 
with enough energy to reach the cancerous cells. After traveling 
the specified distance protons stop abruptly, depositing most 
of their energy at the targeted cells, sparing harmful radiation 
to the healthy cells behind the tumor. This biologic phenome-
non, of depositing high dose and energy of the beam within the 
tumor while having minimal energy deposited beyond the tumor 
is known as the Bragg Peak Effect. During radiation treatment, 
physicians modify the Bragg peak and extend its distance to cover 
the entire depth of the tumor, ensuring that the entire tumor 
is radiated. Extending the distance of the Bragg Peak is accom-
plished by treating the tumor to different energies, which sends 
multiple sprays of protons to different depths of the tumor. This 
manipulation of the proton beam is called the Spread-Out Bragg 
Peak. Additionally, protons do not deposit much radiation when 
they enter the body. Taking advantage of the Bragg Peak Effect 
and the low entrance dose, proton therapy should theoretically 
achieve less exposure of radiation to normal tissue. This is be-
lieved to lead to higher prescribed doses, reduced complications 
of therapy, and greater efficacy in eradication of the tumor than 
any other form of radiotherapy. 
Methods
Literature for this article was obtained using the Touro College 
Online library, in particular PubMed.
Discussion
Over the past decade, intensity-modulated radiotherapy has be-
come the standard form of radiation treatment for prostate can-
cer, accounting for more than 80% of all radiotherapy (Nguyen 
2011). Although IMRT is the most common method of radiation 
treatment, new forms of treatment are still emerging, most no-
tably proton beam therapy. Proton therapy is currently being 
implemented at various cancer centers across America because 
of the excitement over the radiological advantages protons seem 
to offer. Even though there is a lot of enthusiasm over PBT, no 
factual evidence to prove protons are better than photons has 
been found. The lack of evidence in conjunction with the enor-
mous cost of delivering the treatment is compelling physicians 
to determine if protons are more beneficial. To date there has 
been no clinical study that establishes that protons have a major 
advantage in cancer cure rates. This is because it is difficult to 
conduct cure rate trials, since such differences take many years to 
manifest. Therefore, the initial studies on proton therapy focus on 
treatment related toxicity and quality of life (Pearson et al. 2007). 
The organs most frequently affected by radiation toxicity after 
treatments are the bladder and rectum.
Dosimetric Analysis
A dosimetric analysis is the estimated measurement of ionizing 
radiation from the dose that is absorbed by nearby organs and 
is projected before treatment is delivered. This analysis helps 
physicians determine if there will be toxicity to nearby healthy 
tissue, which can downgrade the patient’s quality of life. A study 
comparing the dosimetry of intensity-modulated radiotherapy 
and proton therapy was conducted to discover if protons spare 
more healthy tissue than photons on the bladder and rectum. Ten 
Figure 1
The graph compares the Bragg peaks of IMRT vs� Proton beam therapy� 
Protons, unlike photons, are clearly seen to delivery most of the radiation at 
the targeted cell� 
(Mohan et al� 2013)
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patients were planned with both three dimensional conformal 
proton therapy and intensity-modulated radiotherapy. The pre-
scribed dose for both treatments was 79.2 cobalt gray-equivalent 
(CGE) to the prostate gland. The study concluded that protons 
reduce the area of nearby healthy tissue that inadvertently re-
ceives low to medium, but not high doses of radiation. In contrast, 
intensity-modulated radiotherapy spreads more low and medi-
um doses of radiation over a larger area of the pelvis (Table 1) 
(Trofimov et al. 2007). IMRT likely ‘bathes’ the pelvis with low to 
medium doses of radiation because it uses multiple ‘beamlets’ to 
target the tumor from different directions. As a result, there are 
more entry points into the patient’s body as radiation is shot 
from the linear accelerator to the tumor.
More significant results were reported by a study from the 
University of Florida. The study also used 10 patients to compare 
proton beam therapy treatment with intensity-modulated radio-
therapy, but with a prescribed dose of 78 CGE (Table 1) (Vargas et 
al. 2008). The difference in results between the study by Trofimov 
et al, in comparison to Vargas et al, can most probably be attribut-
ed to the difference in beam margins and arrangement. To be 
certain the cancerous growth was completely radiated, Trofimov 
et al, added a 10 mm margin around the clinical target volume, 
Vargas et al, only added 5 mm by 8 mm. By minimizing the mar-
gins, Vargas was able to better conform the beam to the tumor. 
When IMRT was delivered both studies used 7 beams, 52° apart 
from each other. However, for proton therapy, only Vargas et al 
optimized the beams. Beam angle optimization means physicians 
determine the ‘beamlet’ angles and intensities, so that the beams 
strike the tumor while sparing as much normal tissue as possible. 
Two steps are taken when determining the correct beam angle 
and intensity. “First, the physicians through their experience and 
intuition decide the arrangement of the beams. Secondly, based 
on the orientation of the beams and the shape of the cancer, 
computer software optimizes the beam intensities.” (Bertsimas 
et al. 2013). 
A clinical investigation conducted by Chera et al, did not use 
beam angle optimization, but used the same prescribed dose and 
similar margins to Vargas et al (Table 1).  Chera et al, concluded 
that the, “use of PBT significantly reduced the dose to normal 
tissues in the pelvis while maintaining adequate target coverage 
compared with IMRT” (Chera et al. 2009). Although the abso-
lute difference between the two treatments was greater in the 
study by Chera et al, Vargas et al, managed to spare slightly more 
healthy tissue.  One can conclude that beam margins play a more 
important role in limiting radiation from healthy tissue than beam 
arrangement. 
In a recent study about the dosimetric impact on anatomical 
movements, Zhang et al, noted that the proton beam is affected 
by compensators that shape the beam at the end of the nozzle. 
As a result, protons experience more scatter than photons and 
minimizing the margins is extremely crucial. Although a dosim-
etric analysis was not the main focus of their study, Zhang et al 
reported that, “The proton therapy plan was better at sparing the 
rectum at doses of less than 50 Gy. However, above 50 Gy, IMRT 
was better at sparing the rectum” (Zhang et al. 2007). Clearly, all 
studies confirm that proton therapy reduces the amount of low 
to medium radiation unintentionally delivered to nearby healthy 
tissue. Yet, IMRT can sometimes yield better conformity to the 
target area in cases where high doses are delivered.
Author Dosimetric Value Bladder Rectum Absolute DifferenceBladder / Rectum
Trofimov
30% CGE 44.5%(IMRT) / 32.8%(PBT) 65.3%(IMRT) / 43.8%(PBT) 11.7% / 21.5%
70% CGE 11.4%(IMRT) / 17.3%(PBT) 9.7%(IMRT) / 10.3%(PBT) 5.9% / 0.6%
Vargas
30% CGE 42.8%(IMRT) / 27.7%(PBT) 55.4%(IMRT) / 20.7%(PBT) 15.1% / 34.7%
78% CGE — 5%(IMRT) / 2.9%(PBT) - / 2.1%
Chera
30% CGE 73.1%(IMRT) / 29.3%(PBT) 71.8%(IMRT) / 22.5%(PBT) 43.8% / 49.3%
70% CGE 9.7%(IMRT) / 9.8%(PBT) 11.5%(IMRT)  / 7.9%(PBT) 0.1% / 3.6%
Table  1
Dosimetric Analysis Comparing IMRT Versus PBT (Pearlstein et� al  2013)
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Toxicity and Quality of Life
Radiation poisoning of healthy tissue caused by protons can ir-
ritate the bladder, cause frequent urination, rectal bleeding, and 
sexual dysfunction. The question is, does toxicity to surrounding 
normal tissue result from the combined low and medium dose 
areas or the high dose area? A clinical investigation compared the 
rate of second cancers between IMRT and 3D-CRT. The study 
found that IMRT almost doubles the amount of second malig-
nancies from 1% to 1.75%. This is because IMRT increases the 
amount of low dose radiation absorbed by surrounding healthy 
tissue (Hall et al. 2003). With this information it should follow 
that proton therapy, which substantially reduces low to medium 
unintentionally absorbed radiation should have significantly lower 
toxicity rates than IMRT. 
A study was launched to discover if proton therapy causes less 
toxicity to nearby organs than intensity-modulated and three-di-
mensional conformal radiotherapy. There were 95 proton thera-
py patients, 153 IMRT patients, and 123 3D-CRT patients. Every 
patient’s bowel and urinary functions were assessed 3, 12, and 24 
months after treatment. The Expanded Prostate Cancer Index 
Composite (EPIC) was used to grade patients that received IMRT. 
Patients that received PBT or 3D-CRT were evaluated with the 
Prostate Cancer Symptom Indices, a similar scale to EPIC. In 
both tests scoring lower signifies lower quality of life. At three 
months following treatment, patients who received 3D-CRT or 
IMRT scored lower on the indices. They reported symptoms of 
urinary irritation, obstruction, incontinence, and a decrease in 
bowel quality of life. Proton therapy patients only reported min-
imal bowel and urinary morbidity. At 12 months all groups were 
equal on the indices when they reported decreased bowel quality 
of life. Only proton therapy patients reported a slight decrease 
in quality of urinary functions, such as irritation and obstruction, 
in comparison to the other groups. By 24 months all groups 
reported minor but clinically meaningful decrements in bowel 
and urinary functions quality of life. Proton therapy had a slight 
advantage for toxicities after 3 months and IMRT and 3D-CRT 
only had a slight advantage for urinary toxicities at 12 months. All 
groups had the same level of toxicity 24 months later. However, 
there are problems with this study. Firstly, each group received a 
slightly different dose to the prostate: 75.6 to 79.2 CGE for the 
IMRT patients, and 74.0 to 82.0 CGE for PBT patients. Different 
doses of radiation could have caused the different patterns of 
toxicity reported by the patients. Also, treatment was delivered 
according to each center’s preferred practice and planning target 
volume margins were not explicitly mandated (Gray et al. 2013). 
Another study on whether PBT can control the incidence of rec-
tal toxicity only comprised of patients receiving the same dose, 
74 CGE. Patients were followed up with after treatment to col-
lect data on the toxicities at 1 month and once every 3 months 
for the first two years and once every 6 months thereafter. The 
rectal toxicities observed included anal pain at defecation and 
rectal bleeding. The bladder toxicities were urinary frequency, 
painful urination, and urinary retention. The patients were graded 
with the Common Toxicity Criteria 4.0, a scale created by the 
National Cancer Institute Grade 1 toxicity usually means minor 
toxicity. Grade 2 means symptoms requiring medications and 
grade 3 means symptoms requiring minor corrective surgery. The 
results revealed that PBT can achieve a low occurrence of grade 
2 rectal toxicities and no major late toxicity was seen. (Nihei et al. 
2011). The study by Nihei et al, takes care of some of the issues of 
the trial by Gray et al, that were mentioned earlier. Each patient 
had the same dose of radiation. In both studies a low amount of 
rectal toxicity is seen early on.
More significant results were found by a study conducted by 
Mendenhall et al. The authors used image-guided proton therapy 
to target the cancerous tissue. They discovered low amounts of 
grade 2 genitourinary and gastrointestinal toxicities (Mendenhall 
et al. 2012). These toxicity results do appear more favorable than 
results commonly reported with IMRT. There was a high inci-
dence of grade 1 and 2, and some patients experienced grade 3 
toxicity. (Valeriani et al. 2014). Even more surprising was the fact 
that Valeriani et al, used image-guided IMRT and the prescribed 
dose was much lower, 68 CGE. The image guided radiation and 
the low amount of radiation should have curtailed the amount of 
toxicity that was reported. 
Only one study reported overall worse gastrointestinal toxic-
ity rates for protons than photons. The study used data from 
Surveillance, Epidemiology, and End Results (SEER), a Medicare 
linked database. Sheets et al, analyzed patient reported outcomes 
based on billing claims for diagnoses and procedures from six-
teen cancer registries. There were 684 patients treated with 
proton therapy and 6666 with IMRT. The authors observed that, 
“proton therapy–treated patients were more likely to receive a 
diagnosis of gastrointestinal morbidity and undergo gastrointes-
tinal procedures” (Sheets et al. 2012). However, this investigation 
did not report information on the prescribed dose and target 
margins. If the dose and margins differed between the two groups 
it could have caused a difference in toxicity rates. Another issue 
with this study is that Sheets et al, used claims for colonoscopy 
to measure gastrointestinal toxicity rates. This would be an im-
precise surrogate for any population. This is the same population 
that might also be more concerned about colonoscopy screening, 
and therefore would receive more gastrointestinal procedures. 
This study should not be used to relay any important morbidity 
information to inquiring patients. The few studies on quality of 
life have only shown modest advantages associated with proton 
therapy in comparison with other forms of radiotherapy.
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Problems with Scatter Beam Proton Therapy
Theoretically, protons should be the superior form of radiation 
treatment because of the Bragg Peak Effect. However, this phe-
nomenon also makes the protons extremely sensitive to uncer-
tainties during treatment. If a physician is unsure how deeply 
situated the tumor is, protons will not destroy the cancerous 
cells if it is not given even energy to reach that area. In contrast, 
photons continue to deposit a substantial amount of radiation 
as they transverse the entire body. As a result, physicians end 
up programming the Spread-Out Bragg Peak to extend deeper 
into the body, irradiating nearby healthy tissue. Additionally, the 
Spread-Out Bragg Peak requires multiple shots of protons to be 
passed through the body to completely radiate the entire depth 
of the tumor. This causes the tissue in the front of the prostate 
to be exposed to many doses of radiation. Additional concerns 
have recently been raised that organ toxicity can also be a result 
of secondary neutrons. Secondary neutrons are created when 
protons collide with the collimator –a metal piece that shapes 
the beam. The collimator is made out of brass and when struck 
by protons it sends off secondary neutrons. Low secondary neu-
tron radiation can cause patients receiving treatment to develop 
a high chance for contracting second malignancies (Brenner et al. 
2008). These neutrons could be stopping PBT from having better 
toxicity results. Although there are simple fixes to reduce the 
amount of neutrons, such as using a material with a low mass 
number, these techniques do not substantially curtail the amount 
of neutrons (Gould 2009). 
Pencil Beam Scanning
Recently, a newer method of delivery has been added to pro-
ton therapy. The older method, Scatter beam uses thick beams 
of passively scattered protons. The beams are shaped through 
slits in metal plates that form a relatively large beam as it exits 
the particle accelerator. The latest improvement to proton beam 
therapy is pencil beam scanning. Also known as spot scanning, this 
method is more accurate version of proton therapy. Pencil beam 
employs an extremely narrow beam that is brushed from side to 
side, ‘painting’ the dose on the tumor spot by spot. Because no 
apertures are needed, the protons do not collide with any metal 
and secondary neutrons are not produced with the collimator. 
The beam targets each spot on the tumor with a specific dose 
of radiation. Pencil beam scanning can even adjust the Spread-out 
Bragg Peak for every individual cancerous cell. “Scattered beam 
and pencil beam can be compared to a painter spraying with a 
spray can versus an airbrush. Instead of needing a stencil to mas-
ter the shape, the proton beam is made ultra fine to define the 
contours and landscape of a tumor” (MD Anderson 2009). With 
pencil beam protons are turned into an intensity-modulated type 
of treatment. This is projected to give protons more conformation 
to the cancer and its surrounding healthy tissues. Recently, a small 
number of cancer centers that deliver proton therapy introduced 
this new technology (Weisenbaugh 2014). To date, it is premature 
to determine if pencil beam is the most optimal method to use 
in the fight against prostate cancer. Only one study concluded 
that there is no toxicity or quality of life differences between 
passively scattered and pencil beam. The clinical investigation was 
comprised of 226 men who received passively scattered proton 
therapy and 65 men who received pencil beam proton therapy. 
Both groups reported similar gastrointestinal toxicity results, 
grade 2, throughout the 24-month trial. Genitourinary toxicity 
was also grade 2 and occurred mostly in the first 12 months 
following treatment. Yet, the authors acknowledged that, “Future 
comparative analyses between spot-scanning and passively scat-
tered are warranted in a larger cohort” (Pugh et al. 2013). 
Conclusion
Proton beam therapy can cure prostatic adenocarcinoma as effi-
ciently as IMRT. If proton therapy would not be extremely expen-
sive this therapy would be less controversial. Protons would have 
been regarded as another type of treatment used to eradicate 
cancerous cells. However, because proton therapy is consider-
ably more expensive it draws criticism to the fact that it only 
has a meager benefit over IMRT. PBT is slightly more effective 
in curtailing the amount of low to medium dose of radiation to 
the nearby organs. However, this only translates into a modest 
advantage in early toxicity over intensity-modulated radiother-
apy. Currently, there is no clinical evidence that proves scatter 
beam proton therapy is a significantly better form of treatment 
than IMRT. However, since there are limited centers that deliver 
proton therapy and relatively few patients that received it, more 
studies need to be conducted to solidify this claim. Although 
scatter beam might not be so advantageous in comparison to 
intensity-modulated radiotherapy, pencil beam proton therapy is 
theorized to turn protons into the ultimate form of treatment. 
More clinical trials need to be conducted to find out if pencil 
beam technology gives proton therapy the edge in the battle 
against prostate cancer.
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